Optimal delay time for the hepatic parenchymal enhancement at the multidetector CT examination.
The objective of this study was to determine the optimal scan delay time after hepatic parenchymal enhancement using a 16-channel multidetector row helical CT (MDCT) scanner. Two hundred fifty-five consecutive patients underwent biphasic CT scans using a 16-channel MDCT. In group A (n = 125), two hepatic venous phase scans (HVP1 and HVP2) were obtained at 40 and 60 seconds, after 100-HU threshold time (T100HU) in the abdominal aorta. In group B (n = 130), HVP1 and HVP2 scans were obtained 50 and 70 seconds after T100HU. Both groups were divided into subgroups that were given different contrast media. Groups A1 and B1 received a contrast medium of 300 mgI/mL; groups A2 and B2 received a contrast medium of 370 mgI/mL. Each patient was injected with contrast medium at a dose of 2 mL/kg at a rate adjusted to the patient's body weight with a constant injection duration of 47 seconds. The attenuation values (HU) for the liver, portal vein, hepatic vein, and aorta were measured. The average HU was compared between the groups. Hepatic enhancement in the images obtained at 50 and 60 seconds after T100HU was greater (P < 0.05) than in images obtained at 40 and 70 seconds. These results were obtained with both contrast media. A few patients showed greater enhancement at a 40 seconds or 70 seconds. Hepatic enhancement was significantly greater in all scans using a contrast medium dose of 370 mgI/mL compared with the 300-mgI/mL dose (P < 0.05). Independent of the concentration of contrast medium, scan delays of 50 to 60 seconds after T100HU may provide optimal hepatic enhancement.
Chung
Yong Eun
YE
Department of Diagnostic Radiology and Research Institute of Radiological Science, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Kim
Ki Whang
KW
Kim
Joo Hee
JH
Lim
Joon Seok
JS
Oh
Young Taik
YT
Chung
Jae-Joon
JJ
Kim
Myeong-Jin
MJ
D000293:Adolescent; D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D002648:Child; D003287:Contrast Media / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007472:Iohexol / Q000493:pharmacokinetics*; D007479:Iopamidol / Q000493:pharmacokinetics*; D008099:Liver / Q000098:blood supply* / Q000000981:diagnostic imaging*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D013997:Time Factors; D036542:Tomography, Spiral Computed / Q000379:methods*
D003287:Contrast Media; D007472:Iohexol; D007479:Iopamidol